Abstract
Targeted alpha therapy (TAT) is a promising approach for the treatment of cancer and infectious diseases. The availability of suitable alpha emitting isotopes in clinically relevant amounts is a main prerequisite for further development of TAT and its widespread clinical application. Several alpha emitting isotopes have been proven effective in preclinical studies and/or clinical trials, including 225Ac / 213Bi, 230U / 226Th, 227Th / 223Ra, 212Pb / 212Bi, 211At and 149Tb. Here we give an overview on methods for the production of these nuclides, describe advantages and limitations of the various processes and give an outlook on future availability and isotope supply.
Keywords: Targeted alpha therapy, alpha emitter, production, uranium-230, thorium-227, thorium-226, actinium-225, radium- 223, bismuth-213, lead-212
Current Radiopharmaceuticals
Title: Production of Alpha Emitters for Targeted Alpha Therapy
Volume: 1 Issue: 3
Author(s): A. Morgenstern, K. Abbas, F. Bruchertseifer and C. Apostolidis
Affiliation:
Keywords: Targeted alpha therapy, alpha emitter, production, uranium-230, thorium-227, thorium-226, actinium-225, radium- 223, bismuth-213, lead-212
Abstract: Targeted alpha therapy (TAT) is a promising approach for the treatment of cancer and infectious diseases. The availability of suitable alpha emitting isotopes in clinically relevant amounts is a main prerequisite for further development of TAT and its widespread clinical application. Several alpha emitting isotopes have been proven effective in preclinical studies and/or clinical trials, including 225Ac / 213Bi, 230U / 226Th, 227Th / 223Ra, 212Pb / 212Bi, 211At and 149Tb. Here we give an overview on methods for the production of these nuclides, describe advantages and limitations of the various processes and give an outlook on future availability and isotope supply.
Export Options
About this article
Cite this article as:
Morgenstern A., Abbas K., Bruchertseifer F. and Apostolidis C., Production of Alpha Emitters for Targeted Alpha Therapy, Current Radiopharmaceuticals 2008; 1 (3) . https://dx.doi.org/10.2174/1874471010801030135
DOI https://dx.doi.org/10.2174/1874471010801030135 |
Print ISSN 1874-4710 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4729 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
PLGA Hollow Microbubbles Loaded with Iron Oxide Nanoparticles and Doxorubicin for Dual-mode US/MR Imaging and Drug Delivery
Current Nanoscience The Akt Pathway: Molecular Targets for Anti-Cancer Drug Development
Current Cancer Drug Targets Noradrenergic Regulation of Glial Activation: Molecular Mechanisms and Therapeutic Implications
Current Neuropharmacology P-Glycoprotein and Breast Cancer Resistance Protein Affect Disposition of Tandutinib, A Tyrosine Kinase Inhibitor
Drug Metabolism Letters Mitosis-Targeting Natural Products for Cancer Prevention and Therapy
Current Drug Targets Molecular Targeting of Breast Cancer: Molecular Imaging and Therapy
Current Pharmaceutical Biotechnology Anticancer Activity of Organogallium(III) Complexes in Colon Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Are Anti-Angiogenic Drugs Useful in Neurodegenerative Disorders?
CNS & Neurological Disorders - Drug Targets Translational Optical Imaging in Diagnosis and Treatment of Cancer
Current Pharmaceutical Biotechnology The Epidermal Growth Factor Receptor as a Therapeutic Target in Glioblastoma Multiforme and other Malignant Neoplasms
Anti-Cancer Agents in Medicinal Chemistry Targeting Brain Cancer Cells by Nanorobot, a Promising Nanovehicle: New Challenges and Future Perspectives
CNS & Neurological Disorders - Drug Targets Targetin g Human Tel omerase by Antisens e Oligonucleotides and Ribozymes
Current Medicinal Chemistry - Anti-Cancer Agents Role of EGFR Monoclonal Antibodies in the Management of Non–small Cell Lung Cancer
Current Cancer Drug Targets Autologous Formalin-Fixed Tumor Vaccine
Current Pharmaceutical Design Patent Selections:
Recent Patents on Anti-Cancer Drug Discovery Sodium Selenite Decreased HDAC Activity, Cell Proliferation and Induced Apoptosis in Three Human Glioblastoma Cells
Anti-Cancer Agents in Medicinal Chemistry Clinical Experience with Therapeutic Vaccines Designed for Patients with Hepatitis
Current Pharmaceutical Design Versatile Applications of microRNA in Anti-Cancer Drug Discovery: From Therapeutics to Biomarkers
Current Drug Discovery Technologies A Literature Review of the Recent Radiotherapy Clinical Trials in Pediatric Brain Tumors
Reviews on Recent Clinical Trials Curcumin: Not So Spicy After All
Mini-Reviews in Medicinal Chemistry